Video: GlaxoSmithKline's Human Papilloma Virus Vaccine to Compete with Merck's Gardasil

The FDA has approved GlaxoSmithKline's (GSK) human papilloma virus vaccine, Cervarix. Competitor Merck (MRK) beat the Glaxo to the market in 2006 with its Gardasil vaccine, which targets the two primary strains of the virus responsible for an estimated three quarters of all cervical cancer cases.

Watch now:

Watch more from the markets now:

Bookmark Market News Live and drop back whenever you need to stay ahead of today's markets.